ASH 2022 | Interim analysis of the FLAIR study: efficacy of ibrutinib plus venetoclax in IgHV unmutated CLL
Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK, discusses results from an interim analysis of the FLAIR study (ISRCTN01844152), which is evaluating ibrutinib-containing regimens in patients with chronic lymphocytic leukemia (CLL). Results have demonstrated that the combination of ibrutinib and venetoclax is able to achieve deep measurable residual disease (MRD) negative remissions, and patients with unmutated IgHV are more likely to achieve MRD negativity. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen, AstraZeneca, Alexion, Sobi, Novartis, Roche, Abbvie, Gilead: Honoraria; Janssen, AstraZeneca, Alexion, Abbvie, Novartis, Roche: Membership on an entity’s Board of Directors or advisory committees.
